| __timestamp | ACADIA Pharmaceuticals Inc. | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 7890000 |
| Thursday, January 1, 2015 | 90804000 | 14456000 |
| Friday, January 1, 2016 | 186456000 | 19218000 |
| Sunday, January 1, 2017 | 255062000 | 27986000 |
| Monday, January 1, 2018 | 265758000 | 47928000 |
| Tuesday, January 1, 2019 | 325638000 | 96388000 |
| Wednesday, January 1, 2020 | 388661000 | 157743000 |
| Friday, January 1, 2021 | 396028000 | 195293000 |
| Saturday, January 1, 2022 | 369090000 | 237374000 |
| Sunday, January 1, 2023 | 402466000 | 295141000 |
| Monday, January 1, 2024 | 359272000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, ACADIA Pharmaceuticals Inc. and Blueprint Medicines Corporation have demonstrated contrasting trajectories in their SG&A expenditures.
From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, reflecting its aggressive expansion and marketing strategies. By 2023, their expenses reached approximately $402 million, highlighting a consistent upward trend.
In contrast, Blueprint Medicines saw a staggering increase of nearly 3,600% in the same period, with expenses peaking at around $295 million in 2023. This rapid growth underscores their strategic investments in administrative capabilities to support their innovative pipeline.
These trends reveal the dynamic nature of financial management in the biotech sector, where strategic spending can drive both growth and innovation.
Johnson & Johnson vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights
ADMA Biologics, Inc. or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and MorphoSys AG
Who Optimizes SG&A Costs Better? ACADIA Pharmaceuticals Inc. or MannKind Corporation
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
ACADIA Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends